TARSUS PHARMACEUTICALS

Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock

01 Aug 2023 21:30:33 By Nasdaq GlobeNewswire

Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock

31 Jul 2023 15:29:44 By Nasdaq GlobeNewswire

Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis

12 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Tarsus to Present at the Jefferies Global Healthcare Conference

05 Jun 2023 07:30:00 By Nasdaq GlobeNewswire

Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements

09 May 2023 15:05:02 By Nasdaq GlobeNewswire

Tarsus Launches “Don’t Freak Out. Get Checked Out.” Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers

08 May 2023 07:30:00 By Nasdaq GlobeNewswire

Tarsus to Participate at the Bank of America 2023 Healthcare Conference

03 May 2023 15:30:00 By Nasdaq GlobeNewswire

Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer

24 Apr 2023 07:30:00 By Nasdaq GlobeNewswire

Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements

13 Mar 2023 15:05:00 By Nasdaq GlobeNewswire

Tarsus to Present at Upcoming Investor Conferences

02 Mar 2023 15:30:00 By Nasdaq GlobeNewswire

Tarsus Added to NASDAQ Biotechnology Index

16 Dec 2022 06:00:00 By Nasdaq GlobeNewswire

Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease

15 Dec 2022 07:30:00 By Nasdaq GlobeNewswire

Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements

09 Nov 2022 06:00:03 By Nasdaq GlobeNewswire

Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting

25 Oct 2022 07:30:01 By Nasdaq GlobeNewswire

Tarsus Announces Transition Plans for Board of Directors

11 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair

06 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Tarsus Launches “Look at the Lids” Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis

29 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings

27 Sep 2022 11:00:00 By Nasdaq GlobeNewswire

Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis

07 Sep 2022 06:00:02 By Nasdaq GlobeNewswire

Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements

11 Aug 2022 15:05:00 By Nasdaq GlobeNewswire